NATR

Business Context and Reporting Period

Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: The Company manufactures and markets nutritional and personal care products (herbal products, vitamins, minerals, personal care items) sold globally through a direct-selling network of independent Distributors and Managers. Operations are segmented into United States, International, and Synergy Worldwide (primarily Asia).

Key Financial Metrics (Fiscal Year 2004)

Margins (as % of Net Sales):
- Cost of Goods Sold: 18.9% (2004) vs 20.0% (2003)
- Volume Incentives: 38.7% (2004) vs 36.1% (2003)
- Selling, General & Administrative: 35.9% (2004) vs 41.0% (2003)
- Effective Income Tax Rate: 25.6% (2004) vs 29.5% (2003)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 27.3% to $331.1 million, driven primarily by a 210.5% surge in the Synergy Worldwide segment (due to operational changes in Japan) and a 16.7% increase in International sales. U.S. sales remained flat, decreasing 0.5%.
• Profitability: Operating income nearly tripled to $21.7 million, and Net Income increased 235% to $17.1 million. This was aided by a lower effective tax rate (25.6%) due to a $2.2 million benefit from a foreign tax asset study.
• Cost Structure: Cost of goods sold as a percentage of sales improved to 18.9% due to manufacturing efficiencies and lower import costs. SG&A expenses decreased as a percentage of sales to 35.9% despite absolute dollar increases related to Synergy expansion.
• Capital Actions: The Company repurchased 1,000,000 shares of common stock via a Dutch Auction tender offer in late 2004 at $16.50 per share, funded by cash and a line of credit.

Outlook, Risks, and Management Commentary

• Guidance & Outlook: Management anticipates continued growth in active Distributors and international markets. A 1.0% price increase in the U.S. market is scheduled for April 1, 2005, to offset raw material costs. SG&A as a percentage of sales is expected to decrease in 2005 due to cost containment.
• Regulatory Risks: Products are subject to FDA, FTC, and international regulations. The Company complied with the FDA ban on ephedra in April 2004. Increased regulatory scrutiny on ingredients like ephedrine and kava has limited product liability insurance availability for certain items.
• Market Risks: Approximately 57% of sales and expenses are realized outside the U.S., exposing the Company to foreign currency fluctuations. Significant devaluation in Venezuela previously adversely affected operations; continued devaluation remains a risk.
• Accounting Changes: The Company will adopt SFAS No. 123R (Share-Based Payment) in 2005, requiring the recognition of stock-based compensation expense, though management does not expect a material effect on results.

Investor Verification Checklist

• Synergy Worldwide Sustainability: Verify if the 210% revenue growth in the Synergy segment is sustainable following the shift from a personal import program to a subsidiary model in Japan.
• Volume Incentive Trends: Monitor the "Volume Incentives" expense ratio (38.7% of sales), which is a significant cost driver and increased slightly year-over-year.
• Foreign Currency Exposure: Assess the impact of currency fluctuations, particularly in Venezuela and other international markets, on future margins.
• Product Liability Reserves: Review the adequacy of self-insurance reserves for product liability claims, given the inability to insure certain ingredients.
• Debt Covenants: Confirm continued compliance with the $15 million line of credit covenants, as $7.5 million was outstanding at year-end.